Key points

In Infants

• The mandatory meningococcal ACWY vaccination program, implemented on January 1, 2025, for infants following an increase in cases of invasive meningococcal infections of types W and Y, has resulted in high vaccination coverage, with nearly 90% of infants born in 2025 having received the first dose of the meningococcal ACWY vaccine.
• Among children born in 2024, before the replacement of the meningococcal C vaccine with the ACWY vaccine, 76.6% had received at least one dose of the tetravalent ACWY meningococcal vaccine by age 21 months. This vaccination coverage is lower than that estimated in 2024 for meningococcal C. It should be noted that vaccination started with a monovalent C vaccine before January 1, 2025, in infants must be continued with a tetravalent ACWY vaccine.
• In 2025, the year the mandatory vaccination against meningococcal B was implemented for infants up to 2 years of age, vaccination coverage against these infections has increased significantly, with 61.7% of infants born in 2024 (aged 21 months) up to date with their vaccinations (compared to 52.1% in 2024).
• Vaccination coverage for other mandatory infant vaccinations is generally very high, with levels close to the 95% target set by the World Health Organization (WHO). In contrast, vaccination coverage against measles, mumps, and rubella is the lowest for the full series, at 88.8%. Given the resurgence of measles virus circulation in France since 2024, it is important to note that vaccination coverage for the two doses against measles, mumps, and rubella must exceed this target to interrupt the circulation of the virus, which can lead to deaths among vulnerable individuals. Verifying and updating this vaccination status is essential for both children and young adults.

In adolescents

• Given the potential severity and increased frequency of invasive meningococcal infections during adolescence, vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults. In 2025, only 15.5% of 11- to 14-year-olds and 7.3% of 15- to 24-year-olds had received a dose of this vaccine. Vaccination against meningococcal ACWY must be stepped up in this age group. Incorporating this vaccination into campaigns conducted in middle schools starting in 2026 will help strengthen protection for young people against these infections. Efforts to improve vaccination coverage must continue in order to achieve herd immunity and reduce the circulation of meningococci in other age groups.
• Vaccination coverage against human papillomavirus (HPV) infections continues to increase, with 53.7% of 16-year-old girls and 32.8% of 16-year-old boys having received a full vaccination series. The gap in vaccination coverage between girls and boys continues to narrow. This progress is encouraging, but vaccination coverage remains insufficient to reduce the incidence of cancers linked to these infections. The national target set by the 10-year cancer control strategy is 80% for both girls and boys by 2030. Efforts must also continue to accelerate the uptake of HPV vaccination to achieve this goal by building on vaccination campaigns in middle schools and reinforcing messages about the importance of vaccinating boys.
  Vaccinating boys is just as essential as vaccinating girls: it contributes to equitable and sustainable protection.

Vaccination Uptake

According to the 2024 Public Health France Barometer, vaccination uptake is high in the region, particularly among young people, with 85.8% of 18- to 25-year-olds stating that they are in favor of vaccination in general.